论文部分内容阅读
目的:观察健脾益髓解毒法联合雄黄对骨髓增生异常综合征患者血清可溶性细胞黏附分子-1(sICAM-1)、转化生长因子β1(TGF-β1)、白血病抑制因子(LIF)的影响.方法:选取我院2014年4月～2016年4月收治的50例骨髓增生异常综合征患者为研究对象,采用随机数字表法将其分为观察组(25例)和对照组(25例),给予对照组常规西药治疗,观察组在此基础上采用健脾益髓解毒法联合雄黄进行治疗,比较两组患者治疗效果,以及血清sICAM-1、TGF-β1和LIF水平、两组患者出现不良反应情况.结果:治疗前两组中医症候积分无显著差异(P＞0.05),治疗后均明显降低(P＜0.05),且观察组显著低于对照组(P＜0.05);观察组总有效率为88.00％,显著高于对照组60.00％(P＜0.05);治疗前两组患者sICAM-1、TGF-β1和LIF水平差异无统计学意义(P＞0.05),治疗后sICAM-1水平显著降低(P＜0.05),TGF-β1、LIF水平明显升高(P＜0.05),观察组变化幅度显著高于对照组(P＜0.05);观察组不良反应发生率为8.00％,显著低于对照组36.00％(P＜0.05).结论:健脾益髓解毒法联合雄黄可以有效改善骨髓增生异常综合征患者血清sICAM-1、TGF-β1和LIF水平,提高治疗总有效率,减少不良反应,具有推广价值.“,”Objective:To discuss the effect of Jianpi Yisui Jiedu Method combined with Realgar on serum soluble intercellular adhesion molecule-1 (sICAM-1), transformation growth factor β1 (TGF-β1) and leukemia inhibitory factor (LIF) levels for patients with myelodysplastic syndrome.Methods:50 cases of patients with myelodysplastic syndrome treated in our hospital from April 2014 to April 2016 were selected as the research subject, who were devided into observation group (with 25 cases) and controlled group (with 25 cases) by the random digital table method.The controlled group were given conventional western medicine treatment, and the observation group were given Jianpi Yisui Jiedu Method combined with Realgar based on it.The treatment effects were compared between the two groups, as well as the serum sICAM-1, TGF-β1 and LIF levels and adverse reactions.Results:There were no significant differences in the TCM syndrome integral scores between the two groups before treatment (P＞ 0.05), which were significantly decreased after treatment (P ＜ 0.05), of which the observation was significantly lower than that of the controlled group (P ＜ 0.05).The total effective rate of the observation group was 88.00％, significantly higher than that of the controlled group (P ＜ 0.05) which was 60.00％.There were no statistical differences in the serum sICAM-1, TGF-β1 and LIF levels between the two groups before treatment (P＞ 0.05), among which the sICAM-1 levels were significantly decreased after treatment, the TGF-β1 and LIF levels obviously increased, and those in the observation group were signifciantly better than those in the controlled group (P ＜ 0.05).The rate of adverse reactions in the observation group was 8.00％, significantly lower than that of 36.00％ in the controlled group (P ＜ 0.05).Conclusion:Jianpi Yisui Jiedu Method combined with Realgar can effectively improve the serum sICAM-1, TGF-β1 and LIF levels of patients with myelodysplastic syndrome, improve the total effective rate and reduce adverse reactions, which has promotion values.